Evidence map›Paper›PMID 34446092›Full record

ReviewCritical care (London, England)2021

Initial antimicrobial management of sepsis.

Michael S Niederman, Rebecca M Baron, Lila Bouadma, Thierry Calandra, Nick Daneman, Jan DeWaele, Marin H Kollef, Jeffrey Lipman, Girish B Nair

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Critical care (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05983861 (Risk Factors for Multidrug Resistant Bacteria at ICU Admission), which is not on this map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05983861 unknown statusnot on this mapstarted 2023, after this paper: background citation

Risk Factors for Multidrug Resistant Bacteria at ICU Admission

TypeobservationalSponsorJosé Raimundo Araujo de AzevedoRan2023 to 2025Enrolled400ConditionsMulti Drug Resistant BacteriaArmsIdentification o Multi Drug Resistant Bacteria
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 165 citations in OpenAlex.

  1. Article
  2. Hour-1 Sepsis Bundle: Updated Evidence.Journal of clinical medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Cell death in sepsis: unveiling new perspectives on organ dysfunction.Frontiers in cell and developmental biology · 2026
    Review
  16. Article
  17. Article
  18. Review
  19. Identification of a novel and high affinity MIF inhibitorJournal of enzyme inhibition and medicinal chemistry · 2025
    Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Michael S NiedermanPulmonary and Critical Care Medicine, New York Presbyterian/Weill Cornell Medical Center, 425 East 61st St, New York, NY, 10065, USA. msn9004@med.cornell.edu.ORCID 0000-0003-0293-386X
Rebecca M BaronHarvard Medical School; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Lila BouadmaAP-HP, Bichat Claude Bernard, Medical and Infectious Diseas ICU, University of Paris, Paris, France.
Thierry CalandraInfectious Diseases Service, Department of Medicine, Lusanne University Hospital, University of Lusanne, Lusanne, Switzerland.
Nick DanemanDivision of Infectious Diseases, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Jan DeWaeleDepartment of Critical Care Medicine, Surgical Intensive Care Unit, Ghent University, Ghent, Belgium.
Marin H KollefDivision of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Jeffrey LipmanRoyal Brisbane and Women's Hospital and Jamieson Trauma Institute, The University of Queensland, Brisbane, Australia.
Girish B NairOakland University William Beaumont School of Medicine, Royal Oak, MI, USA.
Brigham and Women's Hospital · USGhent University Hospital · BENewYork–Presbyterian Hospital · USOakland University · USSunnybrook Health Science Centre · CAThe University of Queensland · AUUniversité Claude Bernard Lyon 1 · FRWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a common consequence of infection, associated with a mortality rate > 25%. Although community-acquired sepsis is more common, hospital-acquired infection is more lethal. The most common site of infection is the lung, followed by abdominal infection, catheter-associated blood steam infection and urinary tract infection. Gram-negative sepsis is more common than gram-positive infection, but sepsis can also be due to fungal and viral pathogens. To reduce mortality, it is necessary to give immediate, empiric, broad-spectrum therapy to those with severe sepsis and/or shock, but this approach can drive antimicrobial overuse and resistance and should be accompanied by a commitment to de-escalation and antimicrobial stewardship. Biomarkers such a procalcitonin can provide decision support for antibiotic use, and may identify patients with a low likelihood of infection, and in some settings, can guide duration of antibiotic therapy. Sepsis can involve drug-resistant pathogens, and this often necessitates consideration of newer antimicrobial agents.

Indexed as

Time FactorsAnti-Infective AgentsBiomarkersHumansSepsisTime-to-TreatmentAnti-Infective AgentsBiomarkersAntibiotic therapyAntimicrobial therapyBacteremiaBiomarkersFungal infectionIntra-abdominal infectionPharmacokineticsPneumoniaSepsis

Identifiers

PMID34446092
PMCPMC8390082
OpenAlexW3194841544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.